Thelansis

 Relapsed or refractory ovarian cancer presents a significant medical challenge, and understanding its implications is crucial. Ovarian cancer (OC) ranks the fifth most prevalent cancer in women and is a leading cause of cancer-related mortality, particularly in the 40–79 age group. The prognosis varies significantly depending on the stage of the disease at the time of diagnosis. Around 70% to 80% of OC patients receive their diagnosis at an advanced stage, resulting in a relatively low 5-year survival rate of approximately 29% to 30%. In contrast, those diagnosed in the early stages of the disease experience a significantly better prognosis, with a ten-year survival rate of 90%, compared to a mere 15% for those diagnosed with advanced-stage disease, even with optimal treatment. Despite advancements in treatment options, nearly 70% of ovarian cancer patients experience relapse following primary cytoreductive surgery and standard first-line chemotherapy. Traditionally, treatment str...